William Blair Brokers Increase Earnings Estimates for APLT

Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) - Equities researchers at William Blair boosted their FY2025 earnings estimates for Applied Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($0.64) per share for the year, up from their previous estimate of ($0.66). The consensus estimate for Applied Therapeutics' current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics' FY2026 earnings at ($0.71) EPS.

APLT has been the subject of a number of other research reports. Wall Street Zen raised Applied Therapeutics to a "sell" rating in a research report on Thursday. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $1.50 target price on shares of Applied Therapeutics in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Applied Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $6.10.

Applied Therapeutics Stock Performance

Shares of NASDAQ APLT traded down $0.00 during trading hours on Monday, hitting $0.41. The stock had a trading volume of 1,900,676 shares, compared to its average volume of 3,352,327. The company has a market capitalization of $58.03 million, a P/E ratio of -0.25 and a beta of 2.00. The firm's 50-day moving average price is $0.42 and its two-hundred day moving average price is $1.66. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million.

Hedge Funds Weigh In On Applied Therapeutics

Several hedge funds have recently added to or reduced their stakes in APLT. AQR Capital Management LLC acquired a new position in Applied Therapeutics in the first quarter valued at about $280,000. Alyeska Investment Group L.P. lifted its stake in Applied Therapeutics by 14.8% in the first quarter. Alyeska Investment Group L.P. now owns 3,107,497 shares of the company's stock valued at $1,519,000 after buying an additional 400,000 shares during the period. Propel Bio Management LLC lifted its stake in Applied Therapeutics by 17.4% in the first quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company's stock valued at $5,517,000 after buying an additional 1,670,000 shares during the period. CreativeOne Wealth LLC lifted its stake in Applied Therapeutics by 132.2% in the first quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock valued at $25,000 after buying an additional 28,701 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Applied Therapeutics by 91.5% in the first quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company's stock valued at $5,076,000 after buying an additional 4,959,670 shares during the period. Institutional investors own 98.31% of the company's stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.